Johannesburg: The South African Health Products Regulatory Authority (SAHPRA) has raised alarms over the rising availability of counterfeit Glucagon-like Peptide-1 (GLP-1) products, including Ozempic, in the local market. These products, designed to lower blood sugar levels and aid in weight loss, are being sold through online platforms and informal channels, posing significant health risks to consumers.
According to South African Government News Agency, SAHPRA has noted a surge in suspected counterfeit versions of Ozempic, scientifically known as semaglutide. This medication, produced by Novo Nordisk, is officially registered in South Africa for managing type 2 diabetes and reducing cardiovascular risks in affected adults. However, it is not authorized for weight management in the country.
SAHPRA has highlighted that Ozempic is available in two pre-filled injectable pen presentations: 0.25 mg and 0.5 mg/dose, and 1 mg/dose. The authority has emphasized the dangers of purchasing non-verified products, urgin
g consumers to avoid such transactions.
Mounjaro, another GLP-1 product developed by Eli Lilly and Company, is also attracting attention but is not yet imported into South Africa through official channels. Like Ozempic, Mounjaro is indicated for treating type 2 diabetes but is not approved for weight management in South Africa.
The regulatory body has pointed out the complexities involved in compounding GLP-1 agonists, noting that the lack of evaluation and unknown ingredients in compounded versions present substantial health risks. Products claiming to contain semaglutide without SAHPRA verification could be substandard and illegal under the Medicines and Related Substances Act.
SAHPRA CEO, Dr. Boitumelo Semete-Makokotlela, emphasized the authority’s commitment to safeguarding public health by monitoring supply chains and investigating any infringements related to the sale of unregistered, falsified medicines. The public is encouraged to report suspected counterfeit products through SAHPRA’s dedicated hot
line or online platform.